A survey to determine the zone of equipoise for the Proximal FEmur Resection or Internal Fixation fOR Metastases (PERFORM) randomized controlled trial
A preliminary zone of equipoise for the PERFORM trial includes patients with 25-75% bone loss, low to moderate risk of operative complications, and life expectancy of at least 6 months. Further stakeholder discussions have finalized the PERFORM trial protocol prior to study initiation.
Authors
- Vincent Y. Ng (ORCID: https://orcid.org/0000-0002-4861-5528)
- Michelle Ghert (ORCID: https://orcid.org/0000-0002-4778-4522)
- R. Lor Randall (ORCID: https://orcid.org/0000-0002-3660-774X)
- Thomas Schubert (ORCID: https://orcid.org/0000-0002-9709-3287)
- Jessa D. Fogel (ORCID: https://orcid.org/0000-0002-9532-7457)
- Ricardo Becker
- Jonathan A. Forsberg (ORCID: https://orcid.org/0000-0003-3835-0615)
- Carol Morris
Institutions
- University of Maryland, Baltimore (US)
- Memorial Sloan Kettering Cancer Center (US)
- Hospital de Clínicas de Porto Alegre (BR)
- UC Davis Health (US)
- UCLouvain (BE)
Publication Details
- Journal
- Trials
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1186/s13063-024-08590-z
- Citations
- 4
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 2.29